Latest Benign prostatic hyperplasia Stories
FDA's Orange Book Updated to Reflect New Vogelxo(TM) Rating MAPLE GROVE, Minn., Feb.
LOS ANGELES, Dec.
The incidence of bladder cancer cases, genealogical malignancies and urinary calculi is expected to drive the U.S.
- FDA-approved product further expands Endo's Branded Pharmaceutical Men's Health portfolio -( )Commercial launch planned for Q1 2015 DUBLIN, Dec.
According to a recent U.S. urology report, increased incidences of benign prostatic hyperplasia (BPH) are expected to be significant in the coming years.
FDA-approved product further expands Endo's Branded Pharmaceutical Men's Health portfolio DUBLIN, Nov.
PLEASANTON, California, November 3, 2014 /PRNewswire/ -- British Journal of Urology International paper underlines need for men with BPH to discuss "male orgasmic
The increase in procedures to treat recurring incidences of urinary and kidney stones will drive the European stone treatment disposables markets, reports iData Research. Vancouver,
With a device necessary for many medical conditions and surgeries, manufacturers of urinary catheters have a safe and stable source of revenue that can withstand the steepest of economic
- A political dynamiter.